


Overview of Approaches Targeting ER Signaling



AI=aromatase inhibitor; CERAN=complete ER antagonist; CoA=coactivator; ER=estrogen receptor; ERE=estrogen response element; PROTAC=PROteolysis Targeting Chimera; SERCA=selective ER covalent antagonist; SERD=selective ER degrader; SERM=selective ER modulator.

■ Light blue denotes investigational agent classes.

© 2025 by Arvinas Operations, Inc. All rights reserved. ARVINAS and the ARVINAS logo are registered trademarks owned by Arvinas Operations, Inc. MED-US-471-2400014


ARVINAS

Pfizer


Overview of Approaches Targeting ER Signaling

AI

Als block the conversion of circulating androgens to estrogens through inhibition of the aromatase enzyme, thereby preventing initiation of the ER signaling pathway through inhibition of estrogen biosynthesis.³



Breast cancer cell



AI=aromatase inhibitor; ER=estrogen receptor; ERE=estrogen response element.

References



AI=aromatase inhibitor; CERAN=complete ER antagonist; CoA=coactivator; ER=estrogen receptor; ERE=estrogen response element; PROTAC=PROteolysis Targeting Chimera; SERCA=selective ER covalent antagonist; SERD=selective ER degrader; SERM=selective ER modulator.


■ Light blue denotes investigational agent classes.

© 2025 by Arvinas Operations, Inc. All rights reserved. ARVINAS and the ARVINAS logo are registered trademarks owned by Arvinas Operations, Inc. MED-US-471-2400014

ARVINAS



Overview of Approaches Targeting ER Signaling



References



AI=aromatase inhibitor; CERAN=complete ER antagonist; CoA=coactivator; ER=estrogen receptor; ERE=estrogen response element; PROTAC=PROteolysis Targeting Chimera; SERCA=selective ER covalent antagonist; SERD=selective ER degrader; SERM=selective ER modulator.


■ Light blue denotes investigational agent classes.

© 2025 by Arvinas Operations, Inc. All rights reserved. ARVINAS and the ARVINAS logo are registered trademarks owned by Arvinas Operations, Inc. MED-US-471-2400014

ARVINAS



Overview of Approaches Targeting ER Signaling



References



AI=aromatase inhibitor; CERAN=complete ER antagonist; CoA=coactivator; ER=estrogen receptor; ERE=estrogen response element; PROTAC=PROteolysis Targeting Chimera; SERCA=selective ER covalent antagonist; SERD=selective ER degrader; SERM=selective ER modulator.


■ Light blue denotes investigational agent classes.

© 2025 by Arvinas Operations, Inc. All rights reserved. ARVINAS and the ARVINAS logo are registered trademarks owned by Arvinas Operations, Inc. MED-US-471-2400014

ARVINAS

Pfizer

Overview of Approaches Targeting ER Signaling




References

AI=aromatase inhibitor; CERAN=complete ER antagonist; CoA=coactivator; ER=estrogen receptor; ERE=estrogen response element; PROTAC=PROteolysis TArgeting Chimera; SERCA=selective ER covalent antagonist; SERD=selective ER degrader; SERM=selective ER modulator.

■ Light blue denotes investigational agent classes.

Overview of Approaches Targeting ER Signaling




References

AI=aromatase inhibitor; CERAN=complete ER antagonist; CoA=coactivator; ER=estrogen receptor; ERE=estrogen response element; PROTAC=PROteolysis Targeting Chimera; SERCA=selective ER covalent antagonist; SERD=selective ER degrader; SERM=selective ER modulator.

■ Light blue denotes investigational agent classes.

Overview of Approaches Targeting ER Signaling



References

AI=aromatase inhibitor; CERAN=complete ER antagonist; CoA=coactivator; ER=estrogen receptor; ERE=estrogen response element; PROTAC=PROteolysis Targeting Chimera; SERCA=selective ER covalent antagonist; SERD=selective ER degrader; SERM=selective ER modulator.

■ Light blue denotes investigational agent classes.

Overview of Approaches Targeting ER Signaling

References

1. Chen P, et al. *Front Endocrinol.* 2022;13:839005. doi:10.3389/fendo.2022.839005.
2. Ferraro E, et al. *Cancer Treat Rev.* 2022;109:102432. doi:10.1016/j.ctrv.2022.102432.
3. Chumsri S, et al. *J Steroid Biochem Mol Biol.* 2011;125(1-2):13-22. doi:10.1016/j.jsbmb.2011.02.001.
4. Pagliuca M, et al. *Crit Rev Oncol Hematol.* 2022;180:103861. doi:10.1016/j.critrevonc.2022.103861.
5. Rej RK, et al. *Cancers (Basel).* 2024;16(3):552. doi:10.3390/cancers16030552.
6. Maximov PY, et al. *Curr Clin Pharmacol.* 2013;8:135-55. doi:10.2174/1574884711308020006.
7. Martinkovich S, et al. *Clin Interv Aging.* 2014;9:1437-52. doi:10.2147/CIA.S66690.
8. Sakamoto KM, et al. *Proc Natl Acad Sci U S A.* 2001;98:8554-9. doi:10.1073/pnas.141230798.
9. Bekes M, et al. *Nat Rev Drug Discov.* 2022;21:181-200. doi:10.1038/s41573-021-00371-6.
10. Gough SM, et al. *Clin Cancer Res.* 2024;30(16):3549-63. doi:10.1158/1078-0432.CCR-23-3465.
11. Chirnomas D, et al. *Nat Rev Clin Oncol.* 2023;20(4):265-78. doi:10.1038/s41571-023-00736-3.
12. Puyang X, et al. *Cancer Discov.* 2018;8:1176-93. doi:10.1158/2159-8290.Cd-17-1229.
13. Parisian AD, et al. *Mol Cancer Ther.* 2024;23:285-300. doi:10.1158/1535-7163.MCT-23-0351.

AI=aromatase inhibitor; CERAN=complete ER antagonist; CoA=coactivator; ER=estrogen receptor; ERE=estrogen response element; PROTAC=PROteolysis Targeting Chimera; SERCA=selective ER covalent antagonist; SERD=selective ER degrader; SERM=selective ER modulator.

■ Light blue denotes investigational agent classes.